STOCK TITAN
  1. Home
  2. Sec-filings
  3. PTHS
  4. [8-K] Pelthos Therapeutics Inc. Reports Material Event

Pelthos Therapeutics (NYSE American: PTHS) grows Zelsuvmi sales but posts $23.4M Q2 loss

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Pelthos Therapeutics Inc. reported strong top-line growth for the quarter ended June 30, 2026, driven by its lead dermatology product Zelsuvmi. Zelsuvmi net product revenue was $15.4 million in the second quarter, up 45% from $10.7 million in the first quarter, with 11,925 units dispensed by 4,571 prescribers and more than 25,000 patients treated since launch.

Total revenue reached $15.6 million for the quarter and $26.5 million for the first half of 2026. However, Pelthos remains unprofitable, posting a second-quarter net loss of $(23.4) million and first-half net loss of $(48.5) million, with Adjusted EBITDA of $(5.7) million improving from $(8.0) million in the prior quarter. Selling, general and administrative expenses rose to $27.7 million, including $5.3 million of non-recurring sales-based milestones and higher royalties.

Cash and cash equivalents were $24.2 million as of June 30, 2026, supported by a $50.0 million senior secured term loan facility with $30.0 million drawn and potential access to an additional $10.0 million, subject to lender discretion. The balance sheet showed total assets of $137.4 million, total liabilities of $138.9 million, and stockholders’ deficit of $(1.5) million. Pelthos highlighted future launches of Xepi in the first quarter of 2027 and Xeglyze in the third quarter of 2027 and noted that previously issued financial statements for the quarter ended March 31, 2026 will be restated.

Positive

  • Zelsuvmi revenue grew 45% quarter-over-quarter to $15.4 million, with units dispensed rising 48% to 11,925, indicating rapid commercial adoption in its first full year of launch.
  • Total net product revenues reached $26.1 million and total revenue $26.5 million for the first half of 2026, establishing a meaningful recurring revenue base.
  • Second-quarter Adjusted EBITDA improved to $(5.7) million from $(8.0) million in the first quarter, reflecting better underlying operating performance despite higher milestone expenses.
  • Pelthos has a $50.0 million term loan facility, with $30.0 million drawn and eligibility for an additional $10.0 million based on revenue, providing financing flexibility alongside $24.2 million in cash.
  • The company is building a three-product FDA-approved portfolio, with planned commercial launches of Xepi in Q1 2027 and Xeglyze in Q3 2027 using the existing Zelsuvmi commercial infrastructure.

Negative

  • Pelthos reported a substantial second-quarter net loss of $(23.4) million and first-half net loss of $(48.5) million, indicating the business is still far from break-even.
  • The balance sheet shows total liabilities of $138.9 million exceeding total assets of $137.4 million, resulting in a stockholders’ deficit of $(1.5) million as of June 30, 2026.
  • The company disclosed that its previously issued March 31, 2026 condensed consolidated financial statements should no longer be relied upon and must be restated, highlighting financial reporting issues.
  • Second-quarter SG&A expenses rose 31% quarter-over-quarter to $27.7 million, outpacing revenue and driven partly by $5.3 million in non-recurring sales-based milestones.
  • Cost of goods sold included a $0.9 million API write-off after inventory fell outside commercial tolerances, underscoring operational and quality-control risk.
  • Interest expense and fair value changes on convertible debt were significant, totaling $6.1 million of other expense in the second quarter, adding to ongoing losses.

Filing Explained

The disclosure shows potential ownership dilution on an as-converted basis, while a $0.9 million API write-off was followed by in-spec manufacturing.

This Form 8-K reports Pelthos’s second-quarter results and corporate presentation as furnished information; the form is used for specified material events. The results and presentation are not deemed filed for Section 18 liability purposes. The filing presents capitalization on an approximately 9.0 million-share as-converted basis, including about 52,128 Series A and 2,600 Series C preferred shares, versus approximately 3.7 million common shares issued and outstanding.

If the preferred shares convert as reflected in that basis, existing common holders’ percentage ownership would be measured against the larger as-converted share count, consistent with the supplied definition of dilution. This disclosure does not state that the conversion occurred in the 8-K.

The release also reports a $0.9 million write-off of commercial API inventory that fell outside specified tolerances. It says the procedural cause was addressed and that subsequent API manufacturing commenced and met specifications.

The comparison table labels the March 31, 2026 figures “As Restated,” while the 8-K directs readers to the company’s Item 4.02 disclosure for the determination that the previously issued interim statements should no longer be relied upon.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report Governance
Previously issued financial statements should no longer be relied upon due to errors or restatements.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Zelsuvmi net product revenue Q2 2026 $15.4 million Second quarter 2026; 45% increase from $10.7 million in first quarter 2026
Total revenue Q2 2026 $15.6 million Three months ended June 30, 2026, including product and license revenue
Net loss Q2 2026 $(23.4) million Three months ended June 30, 2026, compared with $(3.4) million in 2025
Adjusted EBITDA Q2 2026 $(5.7) million Non-GAAP measure; improved from $(8.0) million in first quarter 2026
Cash and cash equivalents $24.2 million Balance as of June 30, 2026 on condensed consolidated balance sheet
Total liabilities $138.9 million As of June 30, 2026; exceed total assets of $137.4 million
Stockholders’ (deficit) equity $(1.5) million As of June 30, 2026, versus $38.9 million equity at December 31, 2025
Zelsuvmi units dispensed Q2 2026 11,925 units Dispensed by 4,571 unique prescribers; 48% quarter-over-quarter increase
Adjusted EBITDA financial
"Adjusted EBITDA for the second quarter of 2026 was $(5.7) million"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
senior secured term loan facility financial
"we entered into a $50.0 million senior secured term loan facility with Horizon Technology Finance"
A senior secured term loan facility is a type of borrowed money that a company takes out, which is backed by its valuable assets like property or equipment. Because it is secured by these assets and ranks higher in repayment priority, it is considered safer for lenders and typically offers lower interest rates. For investors, it provides a relatively stable and priority claim on the company's assets if it encounters financial difficulties.
stockholders' (deficit) equity financial
"Total stockholders' (deficit) equity | $ (1,501)"
change in fair value of convertible debt financial
"Change in fair value of convertible debt | (3,705)"
inventory valuation step-up financial
"the inventory valuation step-up recognized in cost of goods sold resulting from the July 1, 2025 acquisition"
molluscum contagiosum medical
"molluscum contagiosum, a highly contagious viral skin infection that largely afflicts children"
Molluscum contagiosum is a common viral skin infection that causes small, painless bumps or lesions on the skin. While it primarily affects children and healthy adults, it can spread easily through skin contact. For investors, understanding health conditions like this highlights the importance of healthcare companies involved in treatments and the potential impact of infectious diseases on public health and economic stability.
Total revenue Q2 2026 $15.6 million Increased from $0 in Q2 2025 as commercial operations ramped
Net loss Q2 2026 $(23.4) million Widened from $(3.4) million in Q2 2025 with higher SG&A and financing costs
Zelsuvmi revenue QoQ $15.4 million Up 45% from $10.7 million in the first quarter of 2026
Adjusted EBITDA Q2 2026 $(5.7) million Improved from $(8.0) million in the first quarter of 2026

FAQ

How did Pelthos Therapeutics (PTHS) perform financially in the second quarter of 2026?
Pelthos reported Q2 2026 revenue of $15.6 million, driven mainly by Zelsuvmi sales, and a net loss of $(23.4) million. For the first half of 2026, total revenue was $26.5 million with a cumulative net loss of $(48.5) million.

What growth did Pelthos Therapeutics (PTHS) see for Zelsuvmi in Q2 2026?
Zelsuvmi net product revenue rose 45% quarter-over-quarter to $15.4 million, with units dispensed increasing 48% to 11,925. Over four quarters since launch, Zelsuvmi generated $42.3 million in net sales and has been prescribed to more than 25,000 patients.

What is the cash and debt position of Pelthos Therapeutics (PTHS) as of June 30, 2026?
Pelthos held $24.2 million in cash and cash equivalents and has a $50.0 million senior secured term loan facility, with $30.0 million drawn and potential access to another $10.0 million, subject to lender discretion.

Is Pelthos Therapeutics (PTHS) profitable, and what is its Adjusted EBITDA?
Pelthos is not yet profitable, posting a Q2 2026 net loss of $(23.4) million. However, Adjusted EBITDA improved to $(5.7) million in the second quarter from $(8.0) million in the first quarter, reflecting better core operating performance.

What upcoming product launches has Pelthos Therapeutics (PTHS) disclosed?
Pelthos plans to commercialize Xepi, a topical treatment for impetigo, in the first quarter of 2027, and Xeglyze, a head-lice treatment, in the third quarter of 2027, leveraging its existing Zelsuvmi commercial and market access infrastructure.

What accounting or reporting issues has Pelthos Therapeutics (PTHS) identified?
Pelthos indicated in a separate disclosure that its previously issued condensed consolidated financial statements for the quarter ended March 31, 2026 should no longer be relied upon and should be restated, signaling a material financial reporting adjustment.

How leveraged is Pelthos Therapeutics (PTHS) based on the latest balance sheet?
As of June 30, 2026, Pelthos reported total liabilities of $138.9 million and total assets of $137.4 million, resulting in stockholders’ deficit of $(1.5) million, indicating that obligations currently exceed recorded assets.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
false000191924600019192462026-08-132026-08-13

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 13, 2026
PELTHOS THERAPEUTICS INC.
(Exact name of registrant as specified in its charter)
Nevada001-4196486-3335449
(State or other jurisdiction
 of incorporation)		(Commission File Number)(IRS Employer
 Identification No.)
4020 Stirrup Creek Drive, Suite 110
Durham, NC
27703
(Address of registrant’s principal executive office)(Zip code)
Registrant’s telephone number, including area code: (919) 908-2400
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.0001 per sharePTHSThe NYSE American LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o


Item 2.02. Results of Operations and Financial Condition.
On August 13, 2026, Pelthos Therapeutics Inc. (the “Company”) issued a press release summarizing its financial results for the second quarter 2026, as well as providing an update on the Company’s operations. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference.
Readers are encouraged to review the Company's Current Report on Form 8-K filed under Item 4.02 (Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review), which describes the Company's determination that its previously issued condensed consolidated financial statements for the quarter ended March 31, 2026 should no longer be relied upon and should be restated.
The information in this Item 2.02 and Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
Item 7.01. Regulation FD Disclosure.
The information disclosed in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is incorporated into this Item 7.01 by reference.
On August 13, 2026, the Company made available a presentation on its website. A copy of the presentation is attached hereto as Exhibit 99.2. Information contained on the Company’s website is not incorporated by reference into and should not be considered to be part of this Current Report on Form 8-K.
The information contained in this Item 7.01, including Exhibit 99.2 attached hereto, which is incorporated into this Item 7.01 by reference, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing. The information set forth in this Item 7.01 and Exhibit 99.2 attached hereto shall not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.
Forward-Looking Statements

Exhibit 99.2 attached hereto contains, and may indicate, forward-looking statements within the meaning of Section 27A of the Securities Act, Section 21E of the Exchange Act and as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements that express the Company’s intentions, beliefs, expectations, strategies, predictions or any other statements related to the Company’s future activities, or future events or conditions, including without limitation, those statements relating to the success of its products and product candidates, timing, progress and results of any preclinical and clinical trials, its estimates regarding the potential market opportunity for its products and product candidates, its ability to develop its pipeline, its ability to protect its intellectual property and enforce its intellectual property rights, its ability to procure new customers and partners, and its ability to execute its development strategy and sustain its competitive position. Actual future results and trends may differ materially depending on a variety of factors, including, but not limited to, the Company’s limited operating history, its ability to establish its market development capabilities to commercialize its products and generate any revenue, its ability to secure and execute financing transactions, and its ability to maintain regulatory approval of certain of its products, which can be identified by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict, “project,” “seek,” “should,” “target,” “will,” “would” and other similar expressions intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements are not historical facts and are based on current expectations, estimates and projections about the Company’s business based, in part, on assumptions made by its management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict, many of which are beyond the Company’s control. Any forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this Form 8-K, except as required by applicable law.



Item 9.01. Financial Statements and Exhibits
(d)Exhibits:
Exhibit No.Description
99.1
Press Release, dated August 13, 2026
99.2
Company Presentation
104Cover Page Interactive Data File (embedded within the Inline XBRL document)


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 13, 2026
Pelthos Therapeutics Inc.
By:/s/ John M. Gay
Name:John M. Gay
Title:Chief Financial Officer


Exhibit 99.1
image.jpg
Pelthos Therapeutics Announces Second Quarter 2026 Financial Results

Zelsuvmi® net product revenue grew 45% to $15.4 million during the second quarter of 2026 from $10.7 million in the first quarter of 2026

11,925 Zelsuvmi units were dispensed by 4,571 unique prescribers during the second quarter of 2026, representing a 48% quarter-over-quarter increase in units dispensed

More than 25,000 patients have now been prescribed Zelsuvmi since it was commercially launched in July 2025

Management will host a conference call today, August 13, 2026, at 8:30 a.m. ET

DURHAM, N.C., August 13, 2026 — Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos,” “we” or the “Company”), today announced its financial results for the second quarter ended June 30, 2026, which can be found in the Financial Results section of the Company’s website at https://ir.pelthos.com/financial-info/financial-results.

Second Quarter and Recent Highlights

•Zelsuvmi, the first at-home FDA-approved treatment (ages 1 and above) for molluscum contagiosum, a highly contagious viral skin infection that largely afflicts children, was launched in July 2025 and has generated $42.3 million in net sales in the first four quarters of commercial operations.

•As of June 30, 2026, 29,126 units of Zelsuvmi have been dispensed and written by 7,414 unique prescribers. Units of Zelsuvmi dispensed increased from 8,084 in the first quarter of 2026 to 11,925 in the second quarter of 2026, representing a 48% increase. For the first full year, since its commercial launch in July of 2025 through the end of the second quarter of 2026, more than 25,000 patients have been prescribed Zelsuvmi.

•In January 2026, we entered into a $50.0 million senior secured term loan facility with Horizon Technology Finance, of which we drew $30.0 million at the close. Based on the Company achieving trailing twelve-month net product revenues of $42.3 million as of June 30, 2026, we believe we have achieved access to an additional $10.0 million under the Horizon facility, subject to the lender’s discretion.

•The Company’s cash balance as of June 30, 2026 was $24.2 million, which based on its current projections, is expected to support the current business plan.

•As of June 30, 2026, we had approximately 9.0 million shares outstanding on an as-converted basis, which includes the conversion of approximately 52,128 shares of the Company’s Series A and 2,600 shares of Series C Convertible Preferred Stock, and approximately 3.7 million shares of common stock issued and outstanding.

Management Commentary

Scott Plesha, CEO of Pelthos, commented, “The growing adoption of Zelsuvmi and an increasing number of prescriptions written contributed significantly to our strong performance in the second quarter. We expect further growth for Zelsuvmi, with over 4,200 units dispensed in July and total units dispensed since the launch surpassing a significant milestone of 30,000. We believe that our continued commercial success, combined with the Horizon facility, and potential access to additional funds subject to the lender’s discretion, will provide us with the capital and flexibility necessary to advance our business plan. This includes the planned commercialization of Xepi® in the first quarter of 2027 and Xeglyze® in the third quarter of 2027.”


Second Quarter 2026 Financial Summary

•Net product revenue for Zelsuvmi during the second quarter of 2026 was $15.4 million, as compared to $10.7 million in the first quarter of 2026, representing a 45% quarter-over-quarter increase.

•Cost of goods sold was $3.6 million for the second quarter of 2026 compared to $1.7 million in the first quarter of 2026. Cost of goods sold includes fair value adjustments related to finished goods and active pharmaceutical ingredient inventory (“API”) on hand at the time of the Company’s merger in July 2025. Cost of goods sold for the second quarter of 2026 includes a $0.9 million write-off of commercial API inventory identified through the Company’s routine in-process quality control and testing as narrowly falling outside specific tolerances for use in commercial drug product. The underlying procedural cause of these out-of-specification results was addressed and subsequent API manufacturing has commenced and met specifications.

•Selling, general and administrative (“SG&A”) expenses were $27.7 million for the second quarter of 2026, as compared to $21.1 million for the first quarter of 2026, representing a 31% quarter-over-quarter increase. Quarter-over-quarter changes in SG&A included: (i) an increase in royalty and milestone expense of $6.0 million, due primarily to two non-recurring sales based milestones recorded during the second quarter in an amount of $5.3 million, (ii) an increase in cash basis personnel costs of $0.4 million, including $0.5 million of non-recurring severance, (iii) an increase of $0.7 million in non-cash expenses, comprised of stock based compensation and depreciation, and (iv) an increase of $0.7 million in corporate expenses; offset by (v) a reduction in regulatory and manufacturing related expenses of $0.8 million, and (vi) a reduction in marketing, travel, sales and commercial expenses of $0.5 million.

•Interest expense for the second quarter of 2026 and first quarter of 2026, respectively, was $2.4 million. Interest expense is attributable to (i) the Company’s existing convertible notes and its Horizon facility; and (ii) the accounting treatment of certain royalty and purchase agreement obligations entered into by the Company.

•Change in fair value of debt, related to the convertible notes issued in November 2025, was $3.7 million in the second quarter of 2026, as compared to $9.6 million for the first quarter of 2026. At issuance, the Company analyzed the terms of the convertible notes and its embedded features concluding it was appropriate to account for the convertible notes at fair value. Accordingly, the Company initially recognized the convertible notes at fair value and will subsequently measure the convertible notes at fair value with changes in fair value recorded in current period earnings or other comprehensive income.

•Net loss for the second quarter of 2026 was $(23.4) million, as compared to $(25.1) million for the first quarter of 2026.

•Adjusted EBITDA for the second quarter of 2026 was $(5.7) million, as compared to $(8.0) million for the first quarter of 2026, on a comparative basis discussed within the Non-GAAP Financial Information below.

•See additional detail within the Summary Financial Statement tables and Non-GAAP Financial Information below.

Webcast and Conference Call

Management will host a conference call and webcast today at 8:30 a.m. ET to discuss the Company’s second quarter 2026 results and provide a corporate update. Interested parties may participate in the call by dialing:

(877) 451-6152 (Domestic)
(201) 389-0879 (International)
Conference ID: 13761132

The live webcast will be accessible in the Investors section of the Company’s website or by following the direct link:

https://viavid.webcasts.com/starthere.jsp?ei=1767131&tp_key=12eae87cb3


For those who cannot listen to the live broadcast, an online replay will be available in the Investors section of Pelthos’ website.

About Pelthos Therapeutics

Pelthos Therapeutics is a commercial-stage biopharmaceutical company focused on building and advancing a portfolio of differentiated cutaneous infectious disease products that address unmet patient needs. Zelsuvmi® (berdazimer) topical gel, 10.3%, the company’s lead product, is the first and only prescription therapy approved for use at home by patients, parents, and caregivers to treat molluscum contagiosum. The company’s portfolio of assets includes Xepi® (ozenoxacin) Cream, 1%, a topical treatment for impetigo, and Xeglyze® (abametapir), a topical treatment for head lice. More information is available at www.pelthos.com. Follow Pelthos on LinkedIn and X.

Forward-Looking Statements

This press release contains forward-looking statements, as defined in Section 21E of the Securities Exchange Act of 1934, regarding Pelthos’ current expectations. All statements, other than statements of historical fact, could be deemed to be forward-looking statements. In some instances, words such as “plans,” “believes,” “expects,” “anticipates,” and “will,” and similar expressions, are intended to identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect our good faith beliefs (or those of the indicated third parties) and speak only as of the date hereof. These forward-looking statements include, without limitation, references to our expectations regarding (i) our belief that we have achieved access to an additional $10.0 million under the Horizon facility and the likelihood that the lender, in its discretion, will grant access to such additional $10.0 million; (ii) the anticipated ongoing growth for Zelsuvmi; (iii) our belief that our continued commercial performance, paired with the Horizon facility and potential access to additional funds, subject to the lender’s discretion will provide us with the capital and flexibility needed to advance our business plan; (iv) the potential liming for the commercialization and anticipated launch of Xepi and Xeglyze; (v) our belief that the exclusion of certain items in calculating Adjusted EBITDA can provide a useful measure for period-to-period comparisons of our business; and (vi) our belief that Adjusted EBITDA provides useful information to investors in understanding and evaluating our operating results. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ materially from those set forth in such forward-looking statements include, but are not limited to, risks and uncertainties related to there being no guarantee that the trading price of the combined company’s Common Stock will be indicative of the combined company’s value or that the combined company’s Common Stock will become an attractive investment in the future; we may rely on collaborative partners for milestone payments, royalties, materials revenue, contract payments and other revenue projections and may not receive expected revenue; we and our partners may not be able to timely or successfully advance any product(s) in our internal or partnered pipeline or receive regulatory approval and there may not be a market for the product(s) even if successfully developed and approved; and changes in general economic conditions, including as a result of war, conflict, epidemic diseases, the implementation of tariffs, and ongoing or future litigation could expose us to significant liabilities and have a material adverse effect on us. These and other risks and uncertainties are described more fully in our filings with the U.S. Securities and Exchange Commission. The information in this press release is provided only as of the date of this press release, and we undertake no obligation to update any forward-looking statements contained in this press release based on new information, future events, or otherwise, except as required by law.

Contacts

Investors:
LifeSci Advisors, LLC
Mike Moyer, Managing Director
mmoyer@lifesciadvisors.com

Media:
KWM Communications
Kellie Walsh
pelthos@kwmcommunications.com
(914) 315-6072


Summary Financial Statements
Pelthos Therapeutics Inc.
Selected Condensed Consolidated Balance Sheet Data
(unaudited)
(in thousands)
June 30, 2026December 31, 2025
Cash and cash equivalents$24,192 $17,973 
Accounts receivable, net14,482 8,858 
Inventory21,472 23,574 
Total current assets63,356 53,410 
Total assets137,356 130,397 
Accounts payable$5,853 $2,986 
Accrued expenses20,745 15,364 
Total current liabilities31,959 25,993 
Total liabilities138,857 91,516 
Total stockholders' (deficit) equity $(1,501)$38,881 
Total liabilities and stockholders' equity 137,356 130,397 

Pelthos Therapeutics Inc.
Condensed Consolidated Statements of Operations
(unaudited)
(in thousands except share and per share data)

Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Revenue
Net product revenues$15,420 $— $26,085 $— 
License and collaboration revenues183 — 424 — 
Total revenue15,603 — 26,509 — 
Operating expenses
Cost of goods sold3,610 — 5,283 — 
Selling, general and administrative27,673 2,716 48,777 4,356 
Research and development600 515 786 709 
Amortization of intangible assets1,043 — 2,074 — 
Total operating expenses32,926 3,231 56,920 5,065 
Operating loss(17,323)(3,231)(30,411)(5,065)
Other (expense) income
Interest expense(2,389)(218)(4,742)(352)
Change in fair value of convertible debt(3,705)— (13,337)— 
Total other expense(6,094)(218)(18,079)(352)
Net loss before provision for income taxes(23,417)(3,449)(48,490)(5,417)
Provision for income taxes— — — — 
Net loss $(23,417)$(3,449)$(48,490)$(5,417)
Net loss per common share - basic and diluted$(6.62)$(5.29)$(14.15)$(8.56)
Weighted average number of common shares outstanding - basic and diluted3,539,464651,9213,426,232632,513




The table below sets forth the income statement for the second quarter of 2026 and the first quarter of 2026.

Pelthos Therapeutics Inc.
Condensed Consolidated Statements of Operations
(unaudited)
(in thousands except share and per share data)
Three Months Ended
June 30, 2026March 31, 2026
(As Restated)
Revenue
Net product revenues$15,420 $10,665 
License and collaboration revenues183 241 
Total revenue15,603 10,906 
Operating expenses
Cost of goods sold3,610 1,673 
Selling, general and administrative27,673 21,104 
Research and development600 186 
Amortization of intangible assets1,043 1,031 
Total operating expenses32,926 23,994 
Operating loss(17,323)(13,088)
Other (expense) income
Interest expense(2,389)(2,353)
Change in fair value of convertible debt(3,705)(9,632)
Total other expense(6,094)(11,985)
Net loss before provision for income taxes(23,417)(25,073)
Provision for income taxes— — 
Net loss$(23,417)$(25,073)
Net loss per common share -
basic and diluted		$(6.62)$(7.57)
Weighted average number of common shares
outstanding - basic and diluted		3,539,4643,311,742

Non-GAAP Financial Information

Adjusted EBITDA

To provide investors with additional information regarding the Company’s financial results, we have provided within this press release Adjusted EBITDA, a non-GAAP financial measure. We define Adjusted EBITDA as net loss adjusted to eliminate (i) stock-based compensation expense, (ii) the inventory valuation step-up recognized in cost of goods sold resulting from the July 1, 2025 acquisition of LNHC, Inc., as described below, (iii) change in fair value of convertible debt, (iv) non-recurring milestones due to license agreement counterparties, (v) interest expense, (vi) amortization of intangible assets, (vii) depreciation expense, and (viii) the provision for income taxes. We have provided a reconciliation below of Net Loss, the most directly comparable GAAP financial measure, to Adjusted EBITDA.

The Company accounts for business acquisitions using the acquisition method of accounting in accordance with Accounting Standards Codification (“ASC”) 805, Business Combinations. ASC 805 requires, among other things, that assets acquired and liabilities assumed be recognized at their fair values, as determined in accordance with ASC 820, Fair Value Measurements (“ASC 820”), as of the acquisition date. As part of the July 1, 2025 acquisition of LNHC, Inc., the fair value of the inventory acquired was estimated using the top/down method that considers the estimated selling price, costs to complete, disposal costs, profit margin on disposal effort, and holding costs. Significant assumptions include management’s estimates for the selling price and the costs to be incurred related to

the disposal effort of the inventory. The non-cash inventory valuation step-up from the acquisition of LNHC, Inc. is recognized within cost of goods sold in the periods presented.

We have included Adjusted EBITDA in this press release because it is a key measure used by our management to understand and evaluate our core operating performance and trends, to prepare and approve our annual budget and to develop short- and long-term operating plans. In particular, we believe the exclusion of certain items from net loss in calculating Adjusted EBITDA can provide a useful measure for period-to-period comparisons of our business. Accordingly, we believe that Adjusted EBITDA provides useful information to investors in understanding and evaluating our operating results. Our use of Adjusted EBITDA has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our results as reported under GAAP

The following table presents a reconciliation of Net Loss to Adjusted EBITDA for each of the periods indicated (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Net loss $(23,417)$(3,449)$(48,490)$(5,417)
Adjustments:
Stock-based compensation2,760 394 4,668 850 
Cost of goods sold basis step-up2,295 — 3,934 — 
Change in fair value of convertible debt3,705 — 13,337 — 
Non-recurring milestones5,250 — 5,250 — 
Interest expense2,389 218 4,742 352 
Amortization of intangible assets1,043 — 2,074 — 
Depreciation278 — 747 — 
Adjusted EBITDA$(5,697)$(2,837)$(13,738)$(4,215)




1 Corporate Presentation A U G U S T 2 0 2 6 Exhibit 99.2

 

2 Legal Disclaimer This presentation of Pelthos Therapeutics Inc. (“we”, “us”, “our” or the “Company”) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict, “project,” “seek,” “should,” “target,” “will,” “would” or similar expressions and the negatives of those term are intended to identify forward-looking statements. Forward-looking statements reflect management’s current expectations, are based on judgments and assumptions, are inherently uncertain and are subject to risks, uncertainties and other factors, which could cause the Company’s actual results, performance or achievements to differ materially from expected future results, performance or achievements expressed or implied in those forward-looking statements. Examples of these forward-looking statements and the related risks, uncertainties and other factors include, but are not limited to, the following: the success of the launch of the products in our portfolio, timing, progress and results of any preclinical and clinical trials, our estimates regarding the potential market opportunity for our products, our ability to develop our pipeline, our ability to protect our intellectual property and enforce our intellectual property rights, and our ability to execute our development strategy and sustain our competitive position. Actual future results and trends may differ materially depending on a variety of factors, including, but not limited to, the Company’s limited operating history, the Company’s ability to establish our market development capabilities to commercialize our products and generate any revenue, and the Company’s ability to maintain regulatory approvals of products in our portfolio. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Any forward-looking statement in this presentation, in any related presentation supplement and in any related free writing presentation reflects our current view with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our business, results of operations, industry and future growth. You should read this presentation with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

 

33 • Large addressable market with $2,008.50 wholesale acquisition cost (”WAC”) • Launched July 2025 • Modest acquisition cost, unencumbered future revenue stream • Expected launch Q1 2027 • 6–12 million U.S. cases annually • Expected launch Q3 2027 Investment Highlight  Commercial biopharmaceutical company focused on growing, differentiated cutaneous infections product portfolio  Highly synergistic Xepi and Xeglyze product acquisitions leverage Zelsuvmi’s current commercial and market access team and infrastructure  Strong potential revenue streams with >20,000 Zelsuvmi units dispensed from commercial launch in July 2025 through April 2026  Experienced management team to manage execution Product Portfolio

 

4 Corporate Profile Key Data Points (as of 08/10/26, except where noted) PTHSTicker $29.00Stock Price ~9.0MO/S Shares of Common Stock (with Pref A conversion) ~$260MMarket Cap ~51,000 shares (Yahoo) 60-Day Avg. Daily Trading Volume $24.2MCash at end of Q2 2026 Pelthos is a competitive drug portfolio company — committed to commercializing innovative, safe, and efficacious therapeutic products to help patients with unmet dermatological treatment burdens Zelsuvmi: Launched in July 2025. • First and only at home treatment addressing Molluscum contagiosum (“MC”), a large, underserved market treating contagious viral disease Recent portfolio acquisitions: Two FDA-approved complimentary dermatological acquisitions, will leverage Zelsuvmi commercial infrastructure buildout • Xepi (ozenoxacin) Cream 1% - novel topical treatment for impetigo • First line impetigo treatment addresses antimicrobial resistance in pediatric dermatology, drug relaunch expected Q1 2027 • Xeglyze (abametapir) Lotion 0.74% - novel topical treatment for head lice • Commercial launch expected Q3 2027 Experienced management team: Over 20 successful prior drug launches, including Cosentyx, Otezla, Ohtuvayre, Xifaxan

 

5 Management Team John M. Gay | Chief Financial Officer Sai Rangarao | Chief Commercial Officer Scott Plesha | Chief Executive Officer • >30 years of experience in the pharmaceutical industry, including two decades building and leading specialty pharma commercial efforts • President and Chief Commercial Officer at BDSI until it was acquired by Collegium Pharmaceutical in 2022 • Grew BDSI sales from $5 million to $160 million • Previously served as Senior Vice President of Gastrointestinal Sales at Salix Pharmaceuticals. During fifteen-year tenure at Salix, led nationwide salesforce that grew product sales to more than $1.5 billion annually • Earned a BA in Pre-Medicine and Pre-Medical Studies at DePauw University and pursued graduate studies in Dentistry at Indiana University Dental School • >18 years of experience leading, launching, and marketing pharmaceutical products • VP of Marketing & Head of Neurology Sales at Collegium Pharmaceutical • VP of Marketing & Commercial Operations at BDSI, until it was acquired by Collegium in 2022 • Head of US Dermatology Marketing for Otezla at Celgene leading to acquisition by Amgen for $13 Billion • Member of the commercial and marketing organization at Novartis Pharmaceuticals that launched COSENTYX® in the U.S • Earned an MS in Bioscience Regulatory Affairs from The Johns Hopkins University, an MBA and MS from the New Jersey Institute of Technology, and a BS in Computer Science from Indiana University of Pennsylvania • >25 years of experience in public company finance and accounting for life science and technology companies, including R&D and commercial organizations • Raised nearly $300 million in capital and managed various acquisitions, divestitures, integrations and initial public offerings • Corporate Controller for Furiex Pharmaceuticals, Inc., from its initial spin-out transaction, prior to the sale to Forest Labs for $1.1 billion • Earned BAs in Economics and History, and a Master’s in Accounting from the University of North Carolina at Chapel Hill

 

Molluscum & Zelsuvmi Overview

 

7 Molluscum Contagiosum A highly infectious viral condition primarily affecting children 1 year of age or older There are four known types of MC virus (MCV1, 2, 3, 4) with MCV1 being the most common1 Molluscum Contagiosum is caused by a pox virus and is characterized by small, round, firm, umbilicated, often painless bumps. Even after healing, re- infection is possible if in contact with an infected person or object4. ~17 million people infected in the U.S. MC can take up to five years to resolve without treatment2 Peak incidence between 1-10 years of age. Up to 73% of children go untreated3 Point prevalence of 3-6 million children (ages 0-16) in the U.S. Infection, Persistence, and Spread Visible and Psychological ImpactsPain & Skin Irritation Auto- inoculation2 Highly contagious to others ↑ risk of secondary bacterial infections2 Potential worsening of atopic dermatitis Itching, redness Inflammation Anxiety Social withdrawal Untreated Molluscum Contagiosum Has Severe Effects 1) Hebert AA, Bhatia N, Del Rosso JQ. Molluscum Contagiosum: Epidemiology, Considerations, Treatment Options, and Therapeutic Gaps. J Clin Aesthet Dermatol. 2023 Aug;16(8 Suppl 2):S4-S11. PMID: 37636018; PMCID: PMC10453394. 2.)Ludmann P. American Academy of Dermatology. Molluscum contagiosum. 4 October 2023. 3) Basdag H, Rainer BM, Cohen BA. Molluscum contagiosum: to treat or not to treat? Experience with 170 children in an outpatient clinic setting in the northeastern United States. Pediatr Dermatol. 2015;32(3):353-357. doi:10.1111/pde.12504. 4) Schaffer JV, Berger EM. Molluscum Contagiosum. JAMA Dermatol. 2016;152(9):1072. doi:10.1001/jamadermatol.2016.2367. 5) CDC. Clinical Overview of Molluscum Contagiosum. Jan 2025

 

8 Zelsuvmi Has the Potential to Shift MC Treatment Paradigm Previous Treatment Options • Painful, destructive treatments3 • Attractive safety profile demonstrated in clinical trials with no / minimal scarring5,6 • Remaining treatment options such as off-label drugs / natural remedies have unproven efficacy4 • Demonstrated, proven efficacy across key primary and secondary endpoints in clinical trials6 • Necessitates travel to HCP offices, adding to the time burden for MC patients and caregivers2 • First FDA approved medication for molluscum that can be applied at home by patients or caregivers5 • Other available topical treatment requires in-office visits every 3 weeks2 • Daily application that can be started immediately 1.)Least-squares mean count reduction. See Figure 9: Browning JC, Hebert A, Enloe C, Cartwright M, Maeda-Chubachi T. Berdazimer Gel 10.3% is a Clinically Meaningful Therapeutic Intervention for Molluscum Contagiosum. Abstract and poster presented at Fall Clinical 2024. Las Vegas, NV. October 24-27, 2024. 2.) Eichenfield LF, Kwong P, Gonzalez ME, et al. Safety and Efficacy of VP-102 (Cantharidin, 0.7% w/v) in Molluscum Contagiosum by Body Region: Post hoc Pooled Analyses from Two Phase III Randomized Trials. J Clin Aesthet Dermatol. 2021;14(10):42-47. 3.) Hebert AA, Bhatia N, Del Rosso JQ. Molluscum Contagiosum: Epidemiology, Considerations, Treatment Options, and Therapeutic Gaps. J Clin Aesthet Dermatol. 2023;16(8 Suppl 1):S4-S11. 4.) Ong SK, Hoft I, Siegfried E. Analysis of over-the-counter products marketed to treat molluscum contagiosum. Pediatr Dermatol. 2021;38(5):1400-1403. doi:10.1111/pde.14776. 5.) Zelsuvmi Package Insert. 6.) Sugarman JL, Hebert A, Browning JC, et al. Berdazimer gel for molluscum contagiosum: An integrated analysis of 3 randomized controlled trials. J Am Acad Dermatol. 2024;90(2):299-308. doi:10.1016/j.jaad.2023.09.066Ong The 1st & Only At Home Prescription Treatment

 

9 InterventionPopulation Key Study Highlights B-SIMPLE4 Primary OutcomeB-SIMPLE4 Study Locations 1) p-value <0.0001, favoring Zelsuvmi .. Source: Sugarman JL, Hebert A, Browning JC, Paller AS, Stripling S, Green LJ, Cartwright M, Enloe C, Wells N, Maeda-Chubachi T. Berdazimer gel for molluscum contagiosum: An integrated analysis of 3 randomized controlled trials. J Am Acad Dermatol. 2023 Oct 5:S0190-9622(23)02890-6. doi: 10.1016/j.jaad.2023.09.066.Epub ahead of print. PMID: 37804936. Zelsuvmi Efficacy Shown in Phase 3 Clinical Trials Drives Commercial Launch 808 Males, 790 Females Immunocompetent children and adults aged ≥6 months with 3-70 raised MC lesions Mean age: 6.7 years (Range: 0.9 – 76.6 years) 1,598 participants randomized 917 - Zelsuvmi Topical, once-daily application of Zelsuvmi (berdazimer gel, 10.3%) to all active MC lesions for up to 12 weeks 681 - Vehicle Topical, once-daily application of vehicle control gel to all active MC lesions for up to 12 weeks Patients who applied Zelsuvmi for 12 weeks achieved a mean and median reduction in lesion count of 58% and 82%, respectively, compared to 36% and 43% for patients who applied a vehicle control gel Mean Lesion Count Reduction(1) 58.1% 35.7% Zelsuvmi Control 55 Clinics across the US 32.4% of patients treated with Zelsuvmi achieved complete clearance of MC lesions at week 12, compared to 19.7% of patients treated with vehicle control gel in the BSIMPLE-4 pivotal Phase 3 trial Median Lesion Count Reduction(1) 82.4% 42.6% Zelsuvmi Control Safety • Application site reactions were the most common adverse reaction associated with Zelsuvmi • Common application site reactions included mild pain and mild erythema (caused by increased blood flow) • Minimal scarring incidences witnessed

 

10CONFIDENTIAL Baseline Week 2 Week 4 0.0% -1.1 % -43.5% Week 8 -35.7% Week 12 -59.4% -82.4% -42.6% -10.7% - 25 .1% -9.0% -21 .6% - 58 .1% Baseline Week 2 Week 4 0.0% 0.0% -9.5% -10.0% -28.6% -27.8% Week 8 Week 12 Phase 3 Trial Results 1) Figure 9: Browning JC, Hebert A, Enloe C, Cartwright M, Maeda-Chubachi T. Berdazimer Gel 10.3% is a Clinically Meaningful Therapeutic Intervention for Molluscum Contagiosum. Abstract and poster presentedatFall Clinical 2024. Las Vegas, NV. October 24-27, 2024. 2) Figure 10: Browning JC, Hebert A, Enloe C, Cartwright M, Maeda-Chubachi T. Berdazimer Gel 10.3% is a Clinically Meaningful TherapeuticIntervention for Molluscum Contagiosum. Abstract and poster presented at Fall Clinical 2024. Las Vegas, NV. October 24-27, 2024. Least Squares Mean Lesion Reduction(1) P<0.0001 at all time points, favoring Zelsuvmi Median Lesion Reduction(2) Zelsuvmi (n= 917) Vehicle (n= 681) Zelsuvmi showed statistically significant benefit vs. vehicle after 2 weeks of therapy and through out the entire 12-week length of the Phase 3 studies Zelsuvmi (n= 917) Vehicle (n= 681)

 

Zelsuvmi Commercial Overview

 

1212 Data Source: Symphony Health- Metys Data Strong Zelsuvmi Quarter over Quarter Growth Continues Robust growth into first full year of launch

 

1313 Zelsuvmi Covered Lives by Quarter* • Selective contracting strategy • 70% combined Medicaid/commercial coverage with 1 contract • Favorable Gross to Nets • Favorable approval rates with all payers *Clarivate (DRG) Fingertip Formulary • Commercial, Cash and Assistance Programs - 72% of TRxs • Managed and FSS Medicaid - 28% • Medicare <1% of TRxs

 

1414 Strong Sales Team Execution Fully built out commercial team: • 67 Sales Territories Expansion completed & onboarded covering ~53% of MC Claims • Territories expansion complete, contributing to • Zelsuvmi growth • Sales Team targeting: Pediatric/Adult Dermatologists, General Pediatrics, Nurse Practitioners & Physicians Assistants • Territory managers supported by Sales Training, Marketing, Commercial Operations & Market Access teams

 

15 Comprehensive Zelsuvmi Tactical Execution Digital Marketing National & Regional Conference Presence YouTube Promotional Commercial Live & Virtual Educational Speaker Development New Patient Testimonials & HCP Video Series ZELSUVMI GO Patient Support Program

 

Xepi: New Product Acquisition

 

17 Xepi (ozenoxacin) Cream for the treatment of Impetigo Sources: CDC Website, Xepi Pack Insert, FDA.gov • Ozenoxacin cream 1% developed as first line treatment in patients aged 2 months and older • 15 clinical studies in Phase 1 & 2 conducted • Two Pivotal Phase 3 studies conducted in both adult & pediatric patients with impetigo 2 months old and up • Ozenoxacin demonstrated superior clinical and bacteriological outcomes vs. vehicle control Xepi Clinical Story • #1 bacterial infection seen in pediatrician offices, represents 1- 2% of all visits to Pediatricians in the US, with 135M children suffering worldwide • Impetigo is a highly contagious bacterial skin infection, most often caused by Staphylococcus aureus and/or Group A Streptococcus (Streptococcus pyogenes) • Mupirocin resistance is growing significantly in the US Impetigo Facts1 • Strong synergy with existing commercial infrastructure for Zelsuvmi • Significant overlap between Xepi & Zelsuvmi HCP call points • Promotional alignment across Sales, Marketing & Commercial Operations • Anticipated Commercial Launch: Q1 2027 Pelthos Opportunity Acquired from BioFrontera in October 2025 FDA Approved in 2017 Exclusivity until 2032 1https://www.cdc.gov/group-a-strep/about/impetigo.html

 

Xeglyze: New Product Acquisition

 

19 Xeglyze (abametapir) Lotion for the Treatment of Head Lice Sources: CDC Website, Xepi Pack Insert, FDA.gov • Abametapir lotion 0.74% developed as first line treatment in patients aged 6 months of age and older • Phase 2b study completed in 2014 demonstrated 100% ovicidal efficacy • Two Pivotal Phase 3 studies demonstrated that a single, ten- minute application of Xeglyze® results in a statistically significant increase in the proportion of subjects who are cleared of lice versus vehicle. Xeglyze Clinical Story • 100m+ infestations globally, with 6-12m cases in the US, each year with substantial social cost • Increasing resistance to current products containing pyrethrin, permethrin & malathion • Existing products are only effective against lice and not eggs, and most require repeat treatments to break life cycle of infestation, leading to poor compliance and reduced efficacy Head Lice Facts1 • Strong synergy with existing commercial infrastructure for Zelsuvmi and Xepi • Significant overlap between Xeglyze & Zelsuvmi HCP call points • Promotional alignment across Sales, Marketing & Commercial Operations • Anticipated Commercial Launch: Q3 2027 Pelthos Opportunity Acquired from Hatchtech in December 2025 FDA Approved in 2020 Exclusivity until 2034 1https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208945lbl.pdf

 

Summary Financial Statements

 

2121 Summary Balance Sheet • Cash balance included $30 million raised with Horizon Loan Facility in January 2026 with issuance of 5-year term notes; potential access to $10 million as of June 30, 2026, subject to lender discretion; additional tranches totaling $10 million available on hitting certain additional milestones • Working capital of $31.4 million as of June 30, 2026 • Strong stockholder equity position and cash balance provide resources to execute on our business plan Notes

 

2222 Summary Income Statement • Net product revenue increased 45% quarter over quarter • SG&A expenses increased 31% quarter over quarter, related primarily to one-time milestones of ~$5.3 million and royalty increase of ~$0.8 million • SG&A includes milestones & royalties and non-cash expenses (stock-based compensation and depreciation) • SG&A spend supporting current and future net revenue growth Notes

 

Appendix

 

24 Nitricil Platform Pipeline* Approximate Time to NDA Filing Asset DescriptionIndication 7.5 years Berdazimer topical cream, dose TBD, for treatment of mild to moderate atopic dermatitis. Phase 1/2 Clinical stage. SB414 (AD/Psoriasis) 5 years (T. Pedis) 6.5 years (Onychomycosis) Low alcohol berdazimer topical gel for treatment of athlete’s foot with label expansion for onychomycosis following initial approval. Phase 2/3 Clinical stage. SB208 (Tinea Pedis -> Onychomycosis) 6.5 years Low alcohol berdazimer topical gel for treatment of both athlete’s foot and onychomycosis. Phase 2/3 Clinical stage. SB208 (Tinea Pedis + Onychomycosis) 6.5 years Berdazimer topical gel, 10.3% for treatment of external genital and perianal warts. Same active gel (Tube A) as Zelsuvmi but different hydrogel (Tube B) formulation. Phase 3 clinical stage. SB207 (EGW/PAW) *Pelthos has contractual rights to SB207 and would need to enter into a separate license for other indications set forth herein

 

25 NaV1.7 Pipeline Approximate Time to NDA Filing Asset DescriptionIndication 3-4 yearsCC8464 1%, 1.25% and 1.5% ophthalmic solution Phase 1-2a ready CT2000 Eye Drops Chronic Ocular Pain 2-3 yearsCC8464 1%, 1.25% and 1.5% ophthalmic solution Phase 1-2a ready CT2000 Eye Drops Acute Ocular Pain 5+ yearsCC8464 5% and 10% depot injectable Preclinical Stage CT3000 depot Nerve Blocks 5+ yearsCC8464 melt-granulation capsules 50mg, 100mg, 400mg Phase 2 Ready CC8464 Oral Erythromelalgia 5+ yearsCC8464 melt-granulation capsules 50mg, 100mg, 400mg Phase 2 Ready CC8464 Oral Small Fibre Neuropathy 5+ yearsCC8464 melt-granulation capsules 50mg, 100mg, 400mg Phase 2 Ready CC8464 Oral Acute Pain

 

26 Board of Directors Peter Greenleaf, Chairman Richard Baxter Ezra Friedberg Todd Davis Richard Malamut , MD Matt Pauls Scott Plesha Andrew Einhorn

 

27 Operating Leverage All three products utilize the same sales team, with largely overlapping call points, provides greater operating and financial leverage with very little dedicated overhead Portfolio of FDA Approved Products Differentiated portfolio of novel, cutaneous infectious disease products, including Zelsuvmi, Xepi and Xeglyze for the treatment of MC, impetigo and head lice, respectively Barriers to Entry Strong patent portfolio, along with complex, proprietary manufacturing process for Zelsuvmi and complex, multi-step manufacturing process for Xepi provides hefty market protection Significant Unmet Need and Large Market Opportunities Each Pelthos product is differentiated from existing treatment options with considerable market opportunities Strong Financial Position Current balance sheet, revenue growth and strong existing investor support with substantial investable cash provides robust foundation for growth Pipeline Opportunity to exploit legacy Channel clinical programs and work with Ligand to execute on clinical stage programs based on the same Nitricil platform as Zelsuvmi Biopharmaceutical Platform Poised for Growth Strategically positioned to explore and integrate synergistic acquisitions, serving as a platform for investors seeking a strong foothold in the specialty biopharmaceutical market Key Highlights

 

28 Thank You C o n t a c t s I n v e s t o r I n q u i r i e s : M i k e M o y e r L i f e S c i A d v i s o r s , L L C M a n a g i n g D i r e c t o r m m o y e r @ l i f e s c i a d v i s o r s . c o m M e d i a : K W M C o m m u n i c a t i o n s K e l l i e W a l s h / R a c h e l K e s s l e r p e l t h o s @ k w m c o m m u n i c a t i o n s . c o m ( 9 1 4 ) 3 1 5 - 6 0 7 2

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

5 documents

Press Releases

Other Documents